Teladoc short report selloff brings buying opportunity, says Piper Jaffray
Shares of Teladoc Health (TDOC) fell yesterday after a short report raised questions about the company's relationship with Health Insurance Innovations (HIIQ), Piper Jaffray analyst Sean Wieland tells investors in a research note. After speaking with Teladoc's CFO, the analyst believes the "drama is unwarranted," and he encourages investors to take advantage of "another buying opportunity." The CFO told Wieland that Health Insurance is a client of Teladoc under the "visits included" model, which means neither Health Insurance nor the member pay a fee each time the service is used. According to Teladoc, less than 1% of revenue and EBITDA is tied to Health Insurance Innovations, Wieland tells investors in a research note. He believes the short report is "flawed because it relies on inaccurate assumptions and slippery-slope logic." Wieland reiterates an Overweight rating on Teladoc with an $87 price target. The stock closed yesterday down 7.5%, or $4.56, to $56.94.